skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Zach McLellan, Jack Allen, and guest analysts Louisa Joseph and Michael Haydock discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including results for Gilead's new HIV flagship product; Biktarvy, and the US approval of the HIV drug Trogarzo, the first for salvage patients.

Topics covered in this episode include:

  • ODYSSEY CVOT results of Praluent - (SNY REGN AMGN) - 0:39
  • Phase III trial results from patients who switched to Biktarvy from ABC/3TC/DTG (GILD GSK)- 19:47
  • US approval of Trogarzo (TH) - 31:33
  • Phase II results from a study of MOR208 in DLBCL (MOR) - 41:28

Subscribe to this podcast here


Register for HIV webinar






電話:+81 (0)3 6273 4260